Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers

Bhide, S.; Newbold, Kate; Harrington, Kevin; Nutting, Chris

doi:10.1586/era.10.15

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients are treated according to RMH Head and Neck Unit institutional protocols [ 7 , 55 , 56 ]. Patients receiving induction chemotherapy, are treated with either 2 cycles of TPF (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-FU 750 mg/m2 days 1–4) or 2 cycles of CF (cisplatin 75 mg/m2 day1, 5-FU 1000 mg/m2 days 1–4).…”

Section: Methodsmentioning

confidence: 99%

“…Anatomical and functional image data are acquired using RMH clinical systems and backed up on to the RMH clinical picture archiving and storage system (PACS). Anonymised image data are transferred electronically from the clinical PACS to a dedicated research PACS system, based on XNAT [ 56 , 57 ]. Data are extracted from XNAT for subsequent processing, such as the generation of functional imaging parameter maps, and the results are stored within the same XNAT database.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study

et al. 2015

View full text Add to dashboard Cite

BackgroundRadical chemo-radiotherapy (CRT) is an effective organ-sparing treatment option for patients with locally advanced head and neck cancer (LAHNC). Despite advances in treatment for LAHNC, a significant minority of these patients continue to fail to achieve complete response with standard CRT. By constructing a multi-modality functional imaging (FI) predictive biomarker for CRT outcome for patients with LAHNC we hope to be able to reliably identify those patients at high risk of failing standard CRT. Such a biomarker would in future enable CRT to be tailored to the specific biological characteristics of each patients’ tumour, potentially leading to improved treatment outcomes.Methods/designThe INSIGHT study is a single-centre, prospective, longitudinal multi-modality imaging study using functional MRI and FDG-PET/CT for patients with LAHNC squamous cell carcinomas receiving radical CRT. Two cohorts of patients are being recruited: one treated with, and another treated without, induction chemotherapy. All patients receive radical intensity modulated radiotherapy with concurrent chemotherapy. Patients undergo functional imaging before, during and 3 months after completion of radiotherapy, as well as at the time of relapse, should that occur within the first two years after treatment. Serum samples are collected from patients at the same time points as the FI scans for analysis of a panel of serum markers of tumour hypoxia.DiscussionThe primary aim of the INSIGHT study is to acquire a prospective multi-parametric longitudinal data set comprising functional MRI, FDG PET/CT, and serum biomarker data from patients with LAHNC undergoing primary radical CRT. This data set will be used to construct a predictive imaging biomarker for outcome after CRT for LAHNC. This predictive imaging biomarker will be used in future studies of functional imaging based treatment stratification for patients with LAHNC. Additional objectives are: defining the reproducibility of FI parameters; determining robust methods for defining FI based biological target volumes for IMRT planning; creation of a searchable database of functional imaging data for data mining. The INSIGHT study will help to establish the role of FI in the clinical management of LAHNC.Trial registrationNCRI H&N CSG ID 13860

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%